Sino Biopharmaceutical | Sustainability Performance
Conducts research, development, and manufacturing of pharmaceutical products.
2021
China
10,001+ employees
Pharmaceuticals
$1B - 10B in revenue
$100M - 500M in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#9141
Overallⓘ#578
in Chinaⓘ#222
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsEnergy consumptionWaste ManagementWater ManagementAir & land impactNature and biodiversitySocial
Diversity and InclusionPay GapsHealth and SafetyExternalitiesGovernance
SDG ImpactFinancial Data
Business performanceCapital & innovationAnalyst projections
Critical
Critical
Laggard
Critical
Laggard
Intensity
Greenhouse gas intensity Scope 1, 2 (tCO₂e /$M)
Greenhouse gas intensity (Scope 1, 2, 3)(tCO₂e /$M)
Energy consumption (direct) intensity (MWh /$M)
Water consumption intensity (m³ /$M)
Industry Benchmark
47.0
B/M 22.4
67.0
B/M 312.2
111.2
B/M 42.0
681.7
B/M 131.1
Powered by illuminem and GIST Impact
Controversy level
- Sino Biopharmaceutical Limited, Hong Konglisted Chinese pharma major (Tse Ping family), has faced sustained Chinese NMPA enforcement scrutiny over alleged inadequate disclosure of pharmaceutical product quality at multiple Chinese production facilities, plus the contested 2024 Chinese government NRDL (National Reimbursement Drug List) price negotiations affecting Hong Konglisted institutional shareholders.
